Enzymatic vitreolysis with ocriplasmin for symptomatic vitreomacular traction syndrome

• Published in: Acta ophthalmologica (Oxford, England) England), 2017-09, Vol.95 (S259), p.n/a
• Main Authors: Gkizis, I., Garnavou‐Xirou, C., Velissaris, S., Kabanarou, S., Chatziralli, I., Kontou, E., Xirou, T.
• Format: Article
• Language: English
• Subjects: Acuity; Edema; Eye lens; Females; Hole size; Injection; Males; Optical Coherence Tomography; Retina; Side effects; Visual acuity
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2017.0F057

Purpose To evaluate the anatomical and functional outcomes of patients treated with ocriplasmin for vitreomacular traction syndrome (VMT) or macular holes (MH) combined with VMT in a tertiary retina center. Methods Eleven eyes of ten patients (8 females, 2 males) with VMT (8 with VMT alone and 3 with MH combined with VMT) were included in the study. The patients were treated with a single ocriplasmin injection and examined at day 1, 7 and 28 post‐injection. Age, gender, phakic lens status, vitreomacular adhesion diameter, presence of epiretinal membrane, macular hole size, cystoid macular oedema and the status of the ellipsoid zone were recorded. Best‐corrected visual acuity (BCVA) and spectral‐domain‐optical coherence tomography (SD‐OCT) were performed at baseline and at each examination during the follow up period. Adverse effects were also recorded. Results Six eyes (54,5%) presented VMT resolution, while one out of three patients presented MH closure. All patients experienced VMT release by 7 days. Patients with VMT resolution had an increase in BCVA of +0.5 logMAR. . Conclusions Ocriplasmin may be considered as an effective treatment option for VMT and macular holes with VMT.